These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28730667)

  • 1. Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome.
    Kinjo N; Hamada K; Hirayama C; Shimizu M
    J Clin Apher; 2018 Feb; 33(1):117-120. PubMed ID: 28730667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis.
    Miyazono A; Abe J; Ogura M; Sato M; Fujimaru T; Kamei K; Ito S
    Eur J Pediatr; 2014 Dec; 173(12):1557-60. PubMed ID: 23851700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia.
    Shi L; Hu F; Xu C; Zhu H; Qie D; Yuan C; Tao Y; Liu H
    Int J Rheum Dis; 2018 May; 21(5):1142-1145. PubMed ID: 28328098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic plasma exchange in refractory macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a case-based review.
    Liquidano-Perez E; Maza-Ramos G; Salazar-Bailón JL; Yamazaki-Nakashimada MA; Rivas-Larrauri F
    Rheumatol Int; 2023 Jan; 43(1):183-189. PubMed ID: 36264324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult macrophage activation syndrome-haemophagocytic lymphohistiocytosis: 'of plasma exchange and immunosuppressive escalation strategies' - a single centre reflection.
    Lorenz G; Schul L; Schraml F; Riedhammer KM; Einwächter H; Verbeek M; Slotta-Huspenina J; Schmaderer C; Küchle C; Heemann U; Moog P
    Lupus; 2020 Mar; 29(3):324-333. PubMed ID: 32013725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2.
    Tasaki Y; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Wada T; Yachie A
    Cytokine; 2016 Apr; 80():1-6. PubMed ID: 26908294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
    Mizuta M; Shimizu M; Irabu H; Usami M; Inoue N; Nakagishi Y; Wada T; Yachie A
    Rheumatology (Oxford); 2021 Jan; 60(1):231-238. PubMed ID: 32681176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage Activation Syndrome.
    Ravelli A; Davì S; Minoia F; Martini A; Cron RQ
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):927-41. PubMed ID: 26461152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage activation syndrome as a complication of juvenile rheumatoid arthritis.
    An Q; Jin MW; An XJ; Xu SM; Wang L
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4322-4326. PubMed ID: 29077164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan.
    Shimizu M; Nishimura K; Iwata N; Yasumi T; Umebayashi H; Nakagishi Y; Okura Y; Okamoto N; Kinjo N; Mizuta M; Yashiro M; Yasumura J; Wakiguchi H; Kubota T; Mouri M; Kaneko U; Mori M
    Int J Rheum Dis; 2023 May; 26(5):938-945. PubMed ID: 36973039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease.
    Mizuta M; Shimizu M; Inoue N; Kasai K; Nakagishi Y; Takahara T; Hamahira K; Yachie A
    Mod Rheumatol; 2016 Nov; 26(6):929-932. PubMed ID: 27433933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M; Teng L; Xu Y; Xu X
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET in macrophage activation syndrome associated with systemic juvenile idiopathic arthritis.
    Shimizu M; Ikawa Y; Mizuta M; Takakura M; Inoue N; Nishimura R; Yachie A
    Pediatr Int; 2017 Apr; 59(4):509-511. PubMed ID: 28401744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
    Minoia F; Davì S; Horne A; Demirkaya E; Bovis F; Li C; Lehmberg K; Weitzman S; Insalaco A; Wouters C; Shenoi S; Espada G; Ozen S; Anton J; Khubchandani R; Russo R; Pal P; Kasapcopur O; Miettunen P; Maritsi D; Merino R; Shakoory B; Alessio M; Chasnyk V; Sanner H; Gao YJ; Huasong Z; Kitoh T; Avcin T; Fischbach M; Frosch M; Grom A; Huber A; Jelusic M; Sawhney S; Uziel Y; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
    Arthritis Rheumatol; 2014 Nov; 66(11):3160-9. PubMed ID: 25077692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis.
    Juneja M; Jain R; Mishra D
    Kathmandu Univ Med J (KUMJ); 2009; 7(28):411-3. PubMed ID: 20502084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.